Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $26 to $50.
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $26 to $50.